Ignite Creation Date:
2024-05-05 @ 6:36 PM
Last Modification Date:
2024-10-26 @ 9:35 AM
Study NCT ID:
NCT00515554
Status:
COMPLETED
Last Update Posted:
2020-11-13
First Post:
2007-08-10
Brief Title:
HD18 for Advanced Stages in Hodgkins Lymphoma
Sponsor:
University of Cologne
Organization:
University of Cologne
Study Overview
Official Title:
None
Status:
COMPLETED
Status Verified Date:
2020-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is designed to test
1 in patients with negative positron-emission tomography PET after 2 cycles of BEACOPPesc chemotherapy whether the number of cycles can be reduced without compromising progression free survival PFS 2 further cycles vs 6 further cycles
2 for patients with positive PET after 2 cycles whether intensifying BEACOPPesc chemotherapy by adding Rituximab improves PFS
1 in patients with negative positron-emission tomography PET after 2 cycles of BEACOPPesc chemotherapy whether the number of cycles can be reduced without compromising progression free survival PFS 2 further cycles vs 6 further cycles
2 for patients with positive PET after 2 cycles whether intensifying BEACOPPesc chemotherapy by adding Rituximab improves PFS
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None